ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck 1Q Net Rises 67% On Lower Costs; Sales Growth Slows

DOW JONES NEWSWIRES Merck & Co.'s (MRK) first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth. Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin. Merck has said it expects to seek regulatory approval for five new products this year and in 2013, including potential treatments for osteoporosis, insomnia and a next-generation vaccine against a cancer-causing virus. The drug maker also has been focusing on areas such as hepatitis C and diabetes. Merck reported a profit of $1.74 billion, or 56 cents a share, up from $1.04 billion, or 34 cents, a year earlier. Excluding items such as acquisition-related and restructuring costs, earnings rose to 99 cents from 92 cents. Its March projection was earnings of 95 cents to 98 cents a share, below analysts' expectations at the time. Sales rose 1.3% to $11.73 billion, missing the $11.82 billion forecast from analysts polled by Thomson Reuters. Operating margin rose to 21.4% from 14.9%, reflecting a 14% drop in research and development costs. Pharmaceutical sales grew 2.7% to $10.08 billion. Singulair sales edged up 0.9%, while sales of Vytorin declined 8%. The animal-health business, which includes products for farm animals and pets, posted a 8.3% revenue increase. Sales in the consumer division--which includes over-the-counter allergy medicine Claritin and Coppertone skin-care products--rose 7.2%. Shares closed Thursday at $38.47 and were inactive premarket. The stock is up 2% so far this year. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
09/29/201417:56:12Doctor Group Backs Implantable Devices to Prevent Teen Pregnancies
09/24/201421:28:09Correction to Dow Index Overseers Correction
09/24/201421:08:41Correction to Dow Index Overseers Story
09/24/201419:57:00Dow Index Overseers Make It Official: U.S. Firms Only
09/24/201406:29:39German Data Keep European Stocks Recovery in Check -- Update
09/22/201417:11:53MARKET SNAPSHOT: China Growth Concerns Weigh On U.S. Stocks
09/22/201417:07:45Germany's Merck to Buy Sigma-Aldrich for $17 Billion--3rd Update
09/22/201412:43:39Germany's Merck to Buy Sigma-Aldrich for $17 Billion--2nd Update
09/22/201410:27:59MARKET SNAPSHOT: U.S. Stocks Fall; Alibaba Drops After Historic...
09/22/201410:13:19Germany's Merck to Buy Sigma-Aldrich for $17 Billion--Update
09/22/201409:29:37MARKET SNAPSHOT: U.S. Stocks: Futures Lower On China Concerns
09/05/201409:49:05U.S. Hot Stocks: Hot Stocks to Watch
09/04/201415:30:42FDA Approves Merck's Cancer Drug
08/15/201411:00:37Gilead Notches Victory in Hepatitis C Drug Race
07/29/201416:48:45Pfizer Still Looking to Buy; Results Beat Views -- 2nd Update
07/29/201416:33:16MARKET SNAPSHOT: U.S. Stocks End Choppy Trade Lower
07/29/201410:39:16MARKET SNAPSHOT: U.S. Stocks Rise; Dow Above 17,000
07/29/201409:50:28MARKET SNAPSHOT: U.S. Stocks Open Higher; Dow Above 17,000
07/29/201409:33:23MARKET SNAPSHOT: U.S. Stocks: Futures Rise; Housing Prices Next
07/29/201408:15:52MARKET SNAPSHOT: U.S. Stocks: Futures Rise After Merck, Pfizer...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad